FSHR recombinant proteins and antibodies

Follicle-Stimulating Hormone Receptor (FSHR), also known as LGR1, is a G protein-coupled receptor (GPCR) located in reproductive organs such as the ovaries and testes, playing a crucial role in regulating reproductive processes, gonadal function, and hormone secretion. FSHR primarily mediates the effects of follicle-stimulating hormone (FSH) by activating a series of intracellular signaling pathways, promoting follicular development, estrogen synthesis, and spermatogenesis. The role of FSHR in the female reproductive system is particularly significant, as it regulates the development of follicles and ovulation during the ovarian cycle. In males, FSHR is involved in the generation and maturation of sperm in the testes. Due to its central role in reproductive function, FSHR has emerged as a promising target for treating conditions like infertility, premature ovarian failure, and male infertility.

Research on FSHR-targeted therapies mainly focuses on modulating reproductive endocrine function by either agonizing or antagonizing the receptor. FSHR agonists, such as recombinant FSH, are widely used in assisted reproductive treatments like in vitro fertilization (IVF) to stimulate multiple ovulations in the ovaries, increasing the chances of pregnancy. Additionally, FSHR antagonists are being explored in clinical settings to treat conditions such as ovarian hyperstimulation syndrome (OHSS), preventing excessive ovarian stimulation during fertility treatments.

Several biopharmaceutical companies are actively pursuing drug development targeting FSHR. Key areas of research include FSHR agonists, FSHR antagonists, and their applications in infertility treatment. For example, Gedeon Richter has developed recombinant FSH for use in IVF treatments. Additionally, companies like Apexigen are researching FSHR-targeted therapies, exploring how to enhance ovarian function or utilize FSHR antagonists for treating related diseases. In recent years, FSHR-targeted research has expanded beyond female reproductive health to include male infertility and gonadal dysfunction. By developing FSHR-targeted drugs, researchers aim to provide more precise treatment options, particularly in the field of infertility, where there is tremendous potential for improving treatment outcomes.

To assist in the development of FSHR-targeted drugs, DIMA BIOTECH can now provide full-length FSHR recombinant membrane protein developed by its nanodisc membrane protein platform. FSHR nanodisc is an optimal solution for screening small molecules targeting FSHR with its natural structure. Furthermore, DIMA BIOTECH has also prepared a FSHR single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.